Pfizer and BioNTech Launch Coronavirus Vaccine Study for Pregnant Women

With their BNT162b2 coronavirus vaccine now being distributed in major markets to inoculate the general public, Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) have moved to test it on a new group of patients. The two companies announced on Thursday that they have started a global phase 2/3 clinical trial to test the efficacy of the vaccine in pregnant women age 18 and older.